Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m. The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501. BXCL501 is under US FDA review for possible at-home treatment of acute agitation in adults with schizophrenia. Credit: Tapati Rinchumrus/Shutterstock.com. Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m. The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for…

Source: Pharmaceutical Technology